Pfizer raises sales forecast after Q3 2026 earnings beat
Pfizer raised its 2023 revenue forecast to $62.0B-$64.0B, up from $60.5B-$62.5B, and adjusted EPS guidance to $2.95-$3.05. Q3 revenue was $16.6B, flat YoY, with adjusted EPS at 87 cents. Revenue from launched and acquired products rose 32%, while Paxlovid and Comirnaty revenue declined.
How this was made
The 30-second read
Why it matters
Guidance raise is the primary market‑moving event; earnings beat alone was modest.
Market read
Pfizer's upgraded outlook may drive sector‑wide buying in healthcare stocks and influence related ETFs.
What to watch
Potential headwinds from declining Paxlovid and Comirnaty sales may offset revenue gains.
Background
Pfizer reported Q3 results with flat revenue year‑over‑year, but operational growth in non‑COVID products and a new partnership with Innovent Biologics.
Ticker impact
Pfizer raised full-year revenue guidance to $62-64B and EPS to $2.95-$3.05, a $1.5B midpoint increase disclosed for the first time.
upside pressure as investors price in higher revenue and earnings expectations
The new guidance is materially above prior range and includes a $650M charge, indicating robust underlying performance.
Market effects
Boosts outlook for the broader pharma sector as a bellwether raises guidance.
May lift US healthcare index and related ETFs.
Signals continued demand for vaccines and oncology drugs worldwide.
Counterpoint
The $650M in‑licensing charge could weigh on near‑term earnings, suggesting caution.
Key entities
- companyPfizer
US pharmaceutical giant reporting guidance update.
- companyInnovent Biologics
Partner in the $650M in‑licensing and collaboration deal.
